Lipocine (LPCN) Expected to Announce Quarterly Earnings on Thursday

Lipocine (NASDAQ:LPCN) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Lipocine to announce earnings of ($0.39) per share and revenue of $0.16 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. On average, analysts expect Lipocine to post ($1.54) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.

Lipocine Price Performance

NASDAQ:LPCN opened at $1.46 on Wednesday. The company’s 50-day moving average price is $1.96 and its 200-day moving average price is $3.91. Lipocine has a twelve month low of $1.36 and a twelve month high of $12.37.

Insider Transactions at Lipocine

In related news, Director John Higuchi bought 15,970 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was bought at an average cost of $2.23 per share, for a total transaction of $35,613.10. Following the acquisition, the director directly owned 241,365 shares in the company, valued at $538,243.95. This represents a 7.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders acquired 37,568 shares of company stock valued at $82,174. 4.69% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

LPCN has been the subject of several research reports. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Lipocine in a research note on Monday, September 21st. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Lipocine in a research note on Tuesday, September 22nd. Finally, Weiss Ratings upgraded Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.00.

About Lipocine

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.